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Introduction {#s0001}
============

With an incidence of approximately 1 in 700 to 1 in 1000 live births, Down syndrome (DS) or trisomy 21 (OMIM \#190685; [http://www.ncbi.nlm.nih.gov/omim](http://www.ncbi.nlm.nih.omim/gov)) is the most common genetic disorder and the leading genetic cause of intellectual disability. DS is also associated with phenotypes outside the central nervous system, most importantly congenital heart defects, gastrointestinal malformations, facial and skeletal features, autoimmune disease, and signs of premature cellular aging. Although the clinical presentation of DS is highly variable, all affected individuals exhibit cognitive impairment. Intellectual disability can range from mild to moderate, with rare severe cases. Children with DS usually have learning difficulties, delayed language development, impaired memory, and neurobehavioral abnormalities.[@cit0001] In addition, essentially all adults with DS (in the fourth decade of life) develop dementia and neuropathological changes resembling Alzheimer disease. Cognitive impairment in DS has been attributed to progressive neuronal cell death and disruption of neuronal network formation with reduced dendrite branching and synaptic connectivity. Cortical neurons display abnormalities in the length of synaptic contact zones and synaptic density.[@cit0003] Organization of the synaptic network is a highly coordinated process and any perturbations of this network during fetal brain development can be expected to interfere with normal cognitive functions.

Although it has been known since 1959 that DS is caused by an extra copy of chromosome 21,[@cit0007] the mechanisms by which trisomy 21 disrupts development is still not well understood. The DS critical region hypothesis mainly relies on rare cases of partial trisomies, linking imbalance of a small number of genes in specific segments of chromosome 21 to the various clinical phenotypes.[@cit0008] Theoretically, trisomy 21 results in an 1.5-fold increased expression of chromosome 21 genes. However, genes do not function as autonomous units in the genome but are embedded in temporally and spatially highly coordinated regulatory networks. Transcriptome analyses in different human tissues[@cit0010] and DS mouse models[@cit0012] did not reveal a strong (linear) correlation between genomic imbalance and gene expression levels. Expression changes were also observed in genes that are not on chromosome 21 and differed between cell types and tissues. Transcriptomes of fetal fibroblasts from a monozygotic twin pair discordant for DS suggest that differentially expressed genes are organized in large chromosomal domains.[@cit0014] In this context, it is important to emphasize that many genes show extensive expression variation and, even for genes that are dysregulated in DS, there is an extensive overlap of expression levels between normal and DS cohorts. It is plausible to assume that this expression variation significantly contributes to phenotypic variation, modulating the DS phenotypes.[@cit0015] Genetic variation may account for a substantial proportion of this gene expression variation.[@cit0016] However, the functional consequences of epigenetic changes, which occur at a much (one or 2 orders of magnitude) higher rate than DNA sequence changes,[@cit0017] are likely underestimated.

Epigenetic mechanisms control gene expression patterns without altering the DNA sequence. Epigenetic modifications, in particular in DNA methylation are transmitted to daughter cells during somatic cell division and, perhaps also from one generation to the next. CpG islands in promoter regions are usually demethylated. Promoter methylation during development or disease processes is associated with posttranslational histone modifications that lead to a locally condensed inactive chromatin structure and gene silencing.[@cit0018] In contrast, gene body methylation is positively correlated with transcription and may have functions in silencing transposable elements and regulating splicing.[@cit0019] The epigenome is highly plastic during development and susceptible to both internal and environmental cues.[@cit0021] Genome-wide methylation studies have identified epigenetic signatures of DS in several tissues, including leukocytes, skin fibroblasts, buccal cells, liver, placenta,[@cit0023] and brain,[@cit0028] adding another layer of complexity to the highly variable clinical features of DS. Interestingly, chromosome 21 carries several genes, most importantly DNA (cytosine-5)-methyltransferase 3-like (*DNMT3L*), that are key players in epigenetic regulation. Epigenetic dysregulation due to dosage imbalance of chromosome 21 during brain development may provide an important contribution to highly variable cognitive impairment.[@cit0031]

Since methylation patterns are dependent on cell type/tissue, development and differentiation, it is crucial to study the appropriate target tissue and developmental stage for the phenotype of interest. Here we performed a genome-wide methylation analysis of DS fetal frontal cortex, which is essential for higher cognitive functions, such as attention, memory, complex actions, cognition, emotion and behavior.[@cit0032]

Results {#s0002}
=======

Hypermethylation in the developing DS brain {#s0002-0001}
-------------------------------------------

We used Infinium HumanMethylation450 (450K) BeadChips to analyze DNA methylation profiles of 16 DS and 27 control fetal frontal cortex, 8 DS and 8 control fetal temporal cortex, and 2 DS and 9 control adult frontal cortex samples (NCBI GEO accession no. GSE73747; Supplementary Table S1). Control fetuses were from spontaneous or induced abortions with amniotic infection, placental abruption, or other problems, which should not primarily interfere with brain development. To the extent possible, gestational age was matched (*P* = 0.35) between DS (median: 18 weeks, range: 12--42 weeks) and control (median: 20 weeks, range: 15--37 weeks) subjects. In an exploratory analysis based on a multivariate ordination approach, the strongest methylation difference was detected between fetal and adult brain samples, followed by brain region and gestational age. Finally, there was a clear difference between trisomy 21 and controls (Supplementary Fig. S1). We did not find significant effects of sex, postmortem time, or BeadChip.

To identify epigenetic signatures of DS on brain development, we focused our further analysis on the fetal frontal cortices. All together, 8,624 CpG sites (1.85% of all analyzed CpGs) were significantly (FDR-adjusted *P* \< 0.05) hypermethylated and 1,447 (0.31%) hypomethylated, indicating a tendency toward hypermethylation in the DS brain. Global (average of all 465,572 analyzed CpG sites) methylation was 49.8% in DS and 49.5% in control samples, which is a trend difference (Welch T-test; *P* = 0.11). The differentially methylated sites were widespread throughout the genome (Supplementary Fig. S2, upper panel). Compared to other chromosomes, the effect sizes (β differences) of significant sites on chromosome 21 were rather small (Supplementary Fig. S2, lower panel). Chromosomes 19 (2.79%), 21 (2.58%), and 22 (2.25%) were enriched with hypermethylated CpGs (Supplementary Table S2). Compared to the rest of the genome, chromosome 21 was strongly enriched with hypomethylated sites (1.98%). The methylation profile of chromosome 21 in DS cortex appeared to be different from other chromosomes ([Fig. 1](#f0001){ref-type="fig"}). With exception of chromosome 21, all chromosomes displayed an excess (3--11 times) of hypermethylated sites with a maximum methylation change around β values of 0.5. The changes on chromosome 21 were more balanced between hyper- and hypo-methylation with stronger signals toward the extreme ends (0 and 1) of the β value distribution. Figure 1.Plot of methylation changes (β differences) along the distribution of mean methylation levels (range of β values). Only significant changes (adjusted *P* \< 0.05) were considered. The lowess smoother (red line) reveals hypermethylation of all chromosomes except chromosome 21 with a maximum change in the middle range of β values. The changes on chromosome 21 are balanced between hyper- and hypo-methylation with stronger signal toward extreme β values. The methylation data underlying this figure were normalized using the SWAN method; however, the observed genome-wide hypermethylation of all chromosomes except 21 remained stable under various normalization procedures (data not shown).

To further analyze the phenomenon of balanced hyper- and hypo-methylation on chromosome 21, we applied different normalization methods (Dasen with and without BMIQ, Funnorm)[@cit0034] in addition to SWAN,[@cit0037] which was used throughout the study. The observed genome-wide hypermethylation on all chromosomes except 21 remained stable under various normalization procedures when analyzing the entire data set, fetal cortex samples, or fetal frontal cortex samples (data not shown). Moreover, a similar decrease in the density of hypermethylated sites on chromosome 21 was also seen in a published DS blood data set.[@cit0026] In a genomic context, hypermethylated sites were enriched in CpG islands and adjacent north and south shores, whereas hypomethylated CpGs were enriched in north and south shelves (Supplementary Table S2).

For comparison, 49,837 CpGs showed an increase and 25,268 sites a decrease in methylation during gestational development. However, DS and control brains displayed largely identical changes over time. Based on the interaction of chromosomal status (DS versus control) and gestational age in the regression model, only 83 sites were differentially (42 hyper- and 41 hypo-) methylated during development between DS and control brains. When we applied the DNA methylation age calculator,[@cit0038] which relies on only 353 CpG sites, to our fetal brain samples, it correctly predicted prenatal (negative) age. The gestational age was positively correlated with DNA methylation age in both frontal (Pearson\'s *r* = 0.51; *P* = 0.0005) and temporal cortex (*r* = 0.70; *P* = 0.002). The same was true for all samples (*r* = 0.49; *P* = 0.0001). Age acceleration during the fetal period appeared to differ between DS and control brains ([Fig. 2](#f0002){ref-type="fig"}). However, due to the narrow time window (most samples were from the second trimester) and limited sample size, a significant effect as defined by residual projection[@cit0028] could not be demonstrated. Figure 2.DNA methylation age in fetal DS brain. DS fetal cortices are indicated by red and control samples by blue dots. The gestational age of frontal, temporal and all cortex samples is positively correlated with DNA methylation age. The regression lines suggest accelerated DNA methylation aging in DS versus control brains.

A previous study[@cit0029] identified 441 CpG sites with significant methylation (β \> 0.15) changes between DS and control fetal brain samples. Despite differences in tissue (fetal cortex vs. cerebrum), there was a highly significant correlation (*r* = 0.58; *P* = 1E-10) of methylation changes between the reported sites[@cit0029] and our study (Supplementary Fig. S3). In addition, enrichment of the reported sites in our set of significant sites was highly significant (*P* = 1E-10). A smaller subset of 47 pan-tissue DS sites was reported to be hypermethylated in multiple cell types (adult neurons, glia, T cells)/tissues (adult cortex, cerebellum, fetal brain) of DS individuals.[@cit0029] When applying the same filtering criteria (β difference \> 0.15; *P* \< 0.005) as for the definition of pan-tissue DS sites, we found a highly significant overlap (Fisher\'s exact test; OR 3407; *P* = 2.2E-15) of the sites shared between fetal brain (this study) and blood[@cit0026] with the pan-tissue DS sites (Supplementary Fig. S4). Because the reported pan-tissue DS sites are enriched with CTCF binding motifs,[@cit0029] we similarly tested our subset of sites that are hypermethylated in fetal cortex and blood for enrichment with CTCF motifs. We found significant (OR 4.307, *P* = 0.017) enrichment with CTCF_ext and a trend (OR 1.11) enrichment with the CTCF motifs.

Differentially methylated regions (DMRs) {#s0002-0002}
----------------------------------------

Throughout the genome, there were 15,490 promoter regions covered by 3 or more CpG sites on the array. Of the top 100 ranked differentially methylated promoters with at least 3 significant CpGs, 95 were hypermethylated and only 5 hypomethylated in DS (Supplementary Table S3). Only one of the 100 promoters belonged to a gene, adenosine deaminase, RNA-specific, B1 (*ADARB1*) on chromosome 21, compared to 6 on chromosome 19, 3 on chromosome 20, and 4 on chromosome 22 ([Fig. 3](#f0003){ref-type="fig"}). However, considering the low number (117) of analyzed gene promoters on chromosome 21, this is not a significant underrepresentation (Fisher\'s exact test). There were several clusters of differentially methylated promoters outside chromosome 21, most prominently the protocadherin gamma (*PCDHG*) cluster on chromosome 5q31 (with *PCDHGA2, A3, A4, A5, A10, B1*, and *B2* among the top 100 promoters). Figure 3.Chromosomal localization of differentially methylated promoters. Blue dots represent methylation β differences of 15,490 promoters (with \>3 CpG sites on the array) between DS and control cortices. Promoters are mapped to their chromosomal position. Red dots represent the top 100 ranked differentially methylated promoters.

At the gene level (including promoter, exons, introns, 3′ and 5′ UTRs), we identified 69 differentially methylated genes containing at least 3 significant CpG sites with between-group (β \> 0.1) methylation differences ([Table 1](#t0001){ref-type="table"}). With notable exception of the hypomethylated platelet factor 4 (*PF4*), 68 genes were hypermethylated in DS cortex. When ranking genes according to the percentage of differentially methylated sites, our top candidate was tumor necrosis factor receptor superfamily, member 6B (*TNFRSF6B*). However, this gene was covered by only 3 CpGs on the array, which all were significantly hypermethylated. The second ranked gene, carnitine palmitoyltransferase 1B (*CPT1B*), was covered by 18 CpGs, 13 (72%) of which showed increased (β \> 0.1) methylation ([Fig. 4](#f0004){ref-type="fig"}). *CPT1B* was hypermethylated throughout the gene body, but not in the promoter. Only one gene, the potassium channel, voltage gated subfamily E regulatory β subunit 1 (*KCNE1*), was on chromosome 21, which is not a significant underrepresentation. Consistent with the results of promoter methylation analysis, differentially methylated genes were clustered in several regions outside chromosome 21. The strongest cluster with 12 genes was the *PCDHG* cluster on chromosome 5q31 ([Table 1](#t0001){ref-type="table"}). Interestingly, the cadherin, EGF LAG 7-pass G-type receptor 3 (*CELSR3*) on chromosome 3p21.31 was also hypermethylated ([Fig. 4](#f0004){ref-type="fig"}). Additional clusters were identified on chromosome 6p21.3 (*DXO, STK19, TNXB, HLA-DQB2*, and *ZBTB22*), 8q24.3 (*GLI4, FAM83H, ZNF707, KIAA1875, LRRC14*, and *LRRC24*), and 19q13.3 (*NANOS, FKRP, CYTH2, LMTK3*, and *NR1H2*). The distribution of differentially methylated genes was significantly different between chromosomes (Pearson\'s χ^2^ test; *P* = 2.15E-06). Figure 4.Differential methylation of *CPT1B* and *CELSR3*. Red dots represent the methylation level of individual CpGs in DS cortex samples; the blue dots represent control samples. Light blue bars indicate transcribed sequence and orange bars CpG islands. Table 1.Genes with at least 3 significant CpG sites (β difference \> 0.1).GeneNo. of CpGsHypermethylatedHypomethylatedPercentageChromosomal location (bp)[^a^](#t1fn0001){ref-type="fn"}*TNFRSF6B*330100%Chr.20: 62,328,021--62,330,037*CPT1B*1813072%Chr.22: 51,007,290--51,017,899*DND1*64067%Chr.5: 140,050,379--140,053,171*PGAM2*64067%Chr.7: 44,102,326--44,105,186*C2orf27B*53060%Chr.2: 132,552,534--132,559,234*PF4*80450%Chr.4: 74,846,794--74,847,841*NANOS2*63050%Chr.19: 46,416,475--46,418,036*GLI4*94044%Chr 8: 144,349,603--144,359,101*LRRC24*94044%Chr.8: 145,747,761--145,752,416*RAX*188044%Chr.18: 56,934,267--56,941,318*RXFP3*94044%Chr.5: 33,936,491--33,939,023*AK7*104040%Chr.14: 96,858,448--96,955,764*SPRED3*155033%Chr.19: 38,879,061--38,88,6881*RFPL2*134031%Chr.22: 32,586,422--32,600,718*ZNF837*134031%Chr.19: 58,878,985--58,892,427*FKRP*144029%Chr.19: 47,249,303--47,280,245*KIAA1875*185028%Chr.8: 145,162,629--145,173,218*C1orf35*154027%Chr.1: 228,288,427--228,293,112*LRRC14*174024%Chr.8: 145,743,376--145,750,557*WDR55*174024%Chr.5: 140,044,261--140,053,709*PRRT3*133023%Chr.3: 9,987,226--9,994,078*FAM83H*235022%Chr.8: 144,806,103--144,815,971*TOR4A*143021%Chr.9: 140,172,201--140,177,093*CYTH2*194021%Chr.19: 48,972,289--48,985,571*DBNL*194021%Chr.7: 44,084,239--44,109,055*ELANE*163019%Chr.19 :851,014--856,242*SYCE1*163019%Chr.10: 135,367,404--135,382,876*PNPLA2*173018%Chr.11: 818,902--825,573*LMTK3*234017%Chr.19: 48,988,528--49,016,446*DXO*488017%Chr.6: 31,937,587--31,940,069*NME4*244017%Chr.16: 446,725--460,367*ZBTB22*6711016%Chr.6: 33,282,183--33,285,719*CELSR3*376016%Chr.3: 48,673,902--48,700,348*KCNE1*254016%Chr.21: 35,818,988--35,884,573*ZNF707*457016%Chr.8: 144,766,622--144,7960,68*HLA-DQB2*528015%Chr.6: 32,723,875--32,731,311*PCDHGA1*35855015%Chr.5: 140,710,252--140,892,546*CCDC144A*203015%Chr.17: 16,592,851--16,707,767*PCDHGA2*34451015%Chr.5: 140,718,539--140,892,546*PCDHGA3*32642013%Chr.5: 140,723,601--140,892,546*PTRF*243013%Chr.17: 40,554,470--40,575,535*PCDHGB1*30736012%Chr.5: 140,729,828--140,892,546*STK19*718011%Chr.6: 31,938,868--31,950,598*LYPD1*273011%Chr.2: 133,402,426--133,429,152*NOX5*273011%Chr.15: 69,222,864--69,355,083*PCDHGA4*29431011%Chr.5: 140,734,768--140,892,546*PRSS50*414010%Chr.3: 46,753,605--46,854,064*UNC45A*313010%Chr.15: 91,473,410--91,497,323*VPS37B*313010%Chr.12: 123,349,882--123,380,991*GPR39*32309%Chr.2: 133,174,147--133,404,132*PCDHGB2*2792609%Chr.5: 140,739,703--140,892,546*ADAMTS10*33309%Chr.19: 8,645,126--8,675,620*FCGR3A*33309%Chr.1: 161,511,549--161,600,917*FCGR2B*34309%Chr.1: 161,551,101--161,648,444*RTEL1*36308%Chr.20: 62,289,163--62,328,416*RYR1*60508%Chr.19: 38,924,339--39,078,204*PCDHGA5*2662208%Chr.5: 140,743,898--140,892,546*PCDHGB3*2481807%Chr.5: 140,749,831--140,892,546*PCDHGA6*2331607%Chr.5: 140,753,651--140,892,546*KIF25*59407%Chr.6: 168,396,921--168,445,769*MRPS22*63406%Chr.3: 138,724,648--139,076,065*NR1H2*48306%Chr.19: 50,832,910--50,886,239*PCDHGA7*2211205%Chr.5: 140,762,467--140,892,546*MPRIP*71304%Chr.17: 16,945,859--17,120,993*PCDHGB4*204804%Chr.5: 140,767,452--140,892,546*TNXB*5672204%Chr.6: 32,008,931--32,083,111*SPRN*109303%Chr.10: 135,234,170--135,382,916*PCDHGA8*191503%Chr.5: 140,772,381--140,892,546*PTPRN2*1264300.2%Chr.7: 157,331,750--158,380,480[^2]

Recently, a number of genes with differential methylation in multiple DS cell types and tissues (Supplementary Table S4) and enrichment for CTCF sites has been identified.[@cit0029] Nine (*C1orf35, CPT1B, DECR2, FAM83H, GLI4, LRRC14, LRRC24, STK19*, and *TNXB*) of the 10 reported genes with pan-tissue DS DMRs (in T cells, neurons, glia, cerebellum, and fetal brain)[@cit0029] were also hypermethylated in fetal DS cortex. The 10^th^ gene, *CCDC144B*, was hypermethylated in our data set as well but filtered out because it contained only 2 significant CpGs.

Gene ontology (GO) analysis was used for organizing the dysregulated candidate genes into known pathways/processes and predicting functional relevance. Single ranked GOrilla analysis[@cit0039] of promoter regions revealed enrichment for several GO terms (processes) associated with cell adhesion: homophilic cell adhesion via plasma membrane adhesion molecules, cell-cell adhesion, and cell-cell adhesion via plasma-membrane adhesion molecules (Supplementary Table S5). This enrichment was mainly due to genes from the *PCDHG* cluster (A1-A8, A10, A12, and B1-B4). GOrilla analysis of the 69 differentially methylated genes yielded similar results.

Since our data set contained only 2 adult DS brains, we performed an *in silico* analysis on a recently published 450K methylation array data set including 15 DS and 56 control adult cortices.[@cit0028] The top differentially methylated gene in adult brain was *CPT1B*. Consistent with our study, the *PCDHG* genes and *CELSR3* were also hypermethylated. [Fig. 5](#f0005){ref-type="fig"} demonstrates genomic organization of the *PCDHG* genes and similar methylation changes in fetal and adult DS cortices. To test whether the observed methylation changes are brain specific, we re-analyzed the protocadherin gene cluster in another published 450K array data set from blood of 29 DS patients and their relatives.[@cit0026] Methylation of *PCDHG* genes was significantly higher in DS blood, compared to unaffected mothers and siblings (Supplementary Fig. S5). Figure 5.Differential methylation of the *PCDHG* gene cluster in DS brain. The upper part shows the genomic organization of the *PCDHG* gene cluster with exons depicted in orange. The bottom diagrams represent methylation β differences between DS and control samples and average methylation (of all samples) in fetal and adult frontal cortices. Significant methylation differences are indicated by red, non-significant changes by blue bars. Differential methylation is restricted to genes of the A and B but not the C subfamilies and very similar in fetal and adult brains.

Differential methylation is associated with expression changes {#s0002-0003}
--------------------------------------------------------------

Differential methylation of the *PCDHG* gene cluster and *CELSR3* was validated by bisulfite pyrosequencing. All 9 assays for different *PCDHG* genes included the promoter region, while the assay for *CELSR3* targeted the first exon. Methylation was quantified in frontal (16 DS and 28 control), temporal (14 DS and 20 control), and occipital (15 DS and 20 control) fetal cortices as well as in fetal liver (14 DS and 38 controls). Consistent with methylation array results, there was a significant hypermethylation of all analyzed *PCDHG* promoters and *CELSR3* exon 1 in all 4 analyzed tissues (Supplementary Table S6). The methylation values of *PCDHG* promoters were to some extent overlapping in DS and control samples, whereas the *CELSR3* values were clearly separated between groups ([Fig. 6](#f0006){ref-type="fig"}). Adult frontal cortex (of 2 DS and 10 controls) showed the same hypermethylation of *PCDHG* promoters and *CELSR3* as fetal samples. In addition, we sorted neuronal versus non-neuronal cells from fetal and adult cortices using NeuN-specific antibodies.[@cit0040] However, since the fetal brains were not always immunostaining positive, this was only reliable for adult cortex. All tested *PCDHG* genes as well as *CELSR3* showed an increased methylation in neuronal cells from 2 adult DS cortices, compared to 10 controls (Supplementary Table S6). Similar to the previously published pan-tissue DMRs,[@cit0029] the *PCDHG* gene cluster and *CELSR3* were constitutively hypermethylated in DS, affecting multiple tissues and developmental stages. Figure 6.Hypermethylation and expression changes of *PCDHG* genes and *CELSR3* in DS brain. Methylation was measured by bisulfite pyrosequencing. Each dot represents the mean methylation level of one individual DS or control fetal frontal cortex. Expression was measured by targeted RNA sequencing. Blue lines compare median methylation and expression, respectively, between DS and control fetal frontal cortices.

To determine whether the observed methylation changes affect gene expression, we performed targeted RNA sequencing with 15 DS and 20 control fetal frontal cortices. The top differentially methylated genes, in particular the *PCDHG* gene cluster on chromosome 5 were covered by multiple assays. Consistent with their promoter hypermethylation, several *PCDHG* genes (A1, A2, A5, A7, A8, B1-B4) showed significantly lower expression in DS frontal cortex ([Table 2](#t0002){ref-type="table"}). Since many of these genes (A1, A5, B1, B2, and B3) exhibited similar changes in different assays, artifacts can be largely excluded. The strongest transcriptional downregulation was observed for *PCDHGB1, B2*, and *B3* ([Fig. 6](#f0006){ref-type="fig"}). The hypermethylated NADPH oxidase EF-hand calcium binding domain 5 (*NOX5*) ([Table 1](#t0001){ref-type="table"}) and unc-45 myosin chaperone A (*UNC45A*) genes (Supplementary Table S3) on chromosome 15q23 and 15q26.1, respectively, were also transcriptionally downregulated in DS brain. In contrast, hypermethylation of the *CPT1B* gene body and *CELSR3* exon 1 was associated with increased expression ([Fig. 6](#f0006){ref-type="fig"}; [Table 2](#t0002){ref-type="table"}). It is noteworthy that 6 targeted genes on chromosome 21, *APP, BACE2, CBS, DYRK1A, PRDM15*, and *SOD* all showed increased expression, as expected for trisomic genes. Consistent with overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1 A (*DYRK1A*), the neuron-restrictive silencer factor/RE1-silencing transcription factor (*NRSF*/*REST*) was downregulated in DS cortex ([Table 2](#t0002){ref-type="table"}). Unfortunately, expression of *DNMT3L*, which also lies on chromosome 21, was too low for reliable quantification. The *de novo* methyltransferases *DNMT3A* and *DNMT3B* showed significantly reduced expression in DS brain. Table 2.Expression differences of *PCDHG* and other genes between DS and control frontal cortex.Transcript IDlogFCExpression change in DSAverage expressionFDR-adjusted *P* valuePanel 1     6967209_PCDHGA1−0.456Down11.359.68E-06 6967210_PCDHGA1−0.350Down11.602.36E-02 6967206_PCDHGA2−0.423Down9.733.03E-03 6967485_PCDHGA5−0.366Down12.189.52E-04 6967486_PCDHGA5−0.322Down12.863.53E-03 6967483_PCDHGA7−0.307Down11.963.48E-04 6967472_PCDHGA8−0.289Down13.962.87E-02 6967212_PCDHGB1−0.421Down12.768.34E-06 6967213_PCDHGB1−0.556Down11.848.18E-05 6967214_PCDHGB1−0.654Down11.563.77E-10 6966955_PCDHGB2−0.373Down12.921.96E-03 6966956_PCDHGB2−0.493Down13.572.69E-07 6966946_PCDHGB3−0.431Down14.021.12E-06 6966947_PCDHGB3−0.420Down12.212.18E-05 6966948_PCDHGB3−0.277Down11.963.97E-02 6966957_PCDHGB4−0.216Down12.383.21E-03 6722148_PCDHGB8P−0.149Down13.313.78E-02 6839770_NOX5−1.324Down5.191.70E-02 6839780_NOX5−1.022Down4.754.11E-02 6840038_NOX5−1.324Down4.322.87E-02 6871057_CELSR30.211Up13.368.47E-03 6784617_CPT1B0.654Up11.337.09E-05 6784901_CPT1B0.619Up13.182.58E-04 6765192_BACE20.729Up10.374.19E-05 6801576_CBS0.616Up13.552.18E-05 6662528_PRDM150.238Up12.483.97E-02Panel 2     6635788_DNMT3A−0.523Down15.613.77E-07 6970159_DNMT3A−0.431Down10.892.11E-03 6699965_DNMT3B−0.650Down11.861.40E-05 6699954_DNMT3B−0.630Down12.722.52E-05 6715088_NRSF/REST−0.717Down11.992.63E-04 6968017_NRSF/REST−0.520Down11.602.24E-02 6661414_UNC45A−0.403Down13.106.38E-03 6805579_SOD10.331Up17.493.02E-05 6792647_DYRK1A0.380Up14.064.24E-04 6792637_DYRK1A0.233Up16.386.38E-03 6696134_APP0.400Up17.083.62E-03

Comparison of promoter methylation β differences between fetal DS and control cortex (this study) and gene expression changes (logFC differences) in fetal fibroblasts of monozygotic twins discordant for DS[@cit0014] revealed a small negative correlation (Spearman\'s rank *R* = −0.03, *P* = 8.64E-04) for the 15,409 genes that were analyzed in both studies.

Effects of dosage imbalance of epigenetic regulators on chromosome 21 {#s0002-0004}
---------------------------------------------------------------------

The *DNMT3L* gene on chromosome 21q22.4 stimulates de novo methylation by DNMT3A and DNMT3B.[@cit0041] To test whether an extra *DNMT3L* copy is associated with genome-wide methylation changes, we analyzed whole genome bisulfite sequencing data in human embryonic stem cells (hESCs) with disrupted DNMTs.[@cit0042] Hypomethylated CpG islands in *DNMT3A* (FDR-adjusted *P* = 0.02), *DNMT3B* (*P* = 0.02), and double knockout (*P* = 0.03) hESCs were significantly enriched with CpGs that are hypermethylated in DS fetal brains (Supplementary Table S7).

DYRK1A on chromosome 21q22.13 downregulates NRSF/REST.[@cit0043] Of 13,286 NRSF peaks in a previously published ChIP-Seq data set from hESCs (UCSC ENCODE), 2,700 were covered by probes on the 450K array. The top REST target sites (Supplementary Table S8) included *CELSR3* (FDR-adjusted *P* = 2.16E-12) and the *PCDHG* gene cluster (*P* = 0.001 to 0.01 for different genes).

Discussion {#s0003}
==========

The mechanisms underlying cognitive impairment in DS have not yet been fully elucidated. Accumulating evidence suggests that the distinctive behavioral and cognitive deficits, and neuropathological changes are caused by altered regulation and complex interrelations of many genes both on and outside chromosome 21. One strong candidate gene, exemplifying how dosage imbalance of chromosome 21 can lead to genome-wide disturbances is *DYRK1A*. Upregulation of this gene was associated with reduced *REST* mRNA levels in DS fetal cortex (this study) and neurospheres,[@cit0044] leading to dysregulation of genes in close proximity to REST binding sites.[@cit0043] Another key player on chromosome 21 involved in epigenetic regulation is *DNMT3L*. Although it lacks the catalytic domain, DNMT3L cooperates with *de novo* methyltransferases DNMT3A and DNMT3B.[@cit0041] *DNMT3L* is expressed in early developmental stages and at very low levels in some adult tissues, i.e., testis, ovary, and thymus.[@cit0046] As expected for a trisomic gene, Western blots showed significant overexpression of DNMT3L in DS fetal frontal cortex.[@cit0030] In our study, *DNMT3L* mRNA expression was too low to be quantified, whereas both *DNMT3A* and *DNMT3B* were significantly transcriptionally downregulated in DS cortices (mainly from the second trimester). We propose that *DNMT3L* upregulation in neuroprogenitors[@cit0030] leads to increased de novo methylation. Following a wave of *de novo* methylation in early development, hypermethylation may persist in fetal DS brain[@cit0030] and other tissues,[@cit0024] although *DNMT3A* and *DNMT3B* become downregulated. CpG sites that are hypermethylated in DS brains are enriched in regions that are hypomethylated in DNMT3A and/or DNMT3B knockout hESCs, as well as in regions with REST binding sites. Methylation of REST binding sites in DS may facilitate genome-wide methylation. In mouse stem cells it was shown that REST binding is crucial to create or retain a low methylation state.[@cit0047]

Consistent with other genome-wide expression[@cit0010] and methylation studies,[@cit0023] we found an enrichment of differentially methylated CpGs on chromosome 21, with epigenetic dysregulation occurring throughout the genome. Hypermethylated sites (8,624) were 6 times more frequent in fetal DS cortex than hypomethylated sites (1,447). It is noteworthy that chromosome 21 was the only chromosome with a more or less balanced ratio (1.3) of hypomethylated and hypermethylated sites, whereas all other chromosomes showed an excess (3--11 times) of hypermethylated sites. Moreover the β value distribution differed between chromosome 21 and the rest of the genome. Although it is difficult to exclude the possibility that this unique methylation pattern of chromosome 21 is a bioinformatics artifact due to copy number variation, the difference between chromosome 21 and the rest of the genome was observed using various normalization methods in our data set as well as in blood from DS patients.[@cit0026] Thus, it may well have a biological basis. The high number of hypomethylated CpGs fits to our observation that 6 of 7 analyzed chromosome 21 genes were overexpressed in fetal DS cortex.

Arguably, our most interesting candidates for cognitive impairment are the *PCDHG* genes and *CELSR3*, which are hypermethylated in DS brain and enriched for REST binding sites. Protocadherins encode the largest group of the cadherin superfamily of cell-cell adhesion proteins. They are mainly expressed in the developing nervous system, where they play a major role in neural circuit formation via homophilic cell adhesion interactions.[@cit0048] The protocadherin family is subdivided into the clustered and non-clustered protocadherins, in addition to the atypical fat, dachsous, and 7-transmembrane (CELSR) cadherins. The α-, β-, and γ-protocadherins constitute a 1-Mb cluster with 60 genes on chromosome 5q31.[@cit0051] The most thoroughly studied is the gamma cluster, which contains 22 tandemly arranged genes of the A, B, and C subfamilies. Bisulfite pyrosequencing confirmed hypermethylation of several *PCDHG* and the 7-transmembrane cadherin *CELSR3* in DS fetal frontal, temporal, and occipital cortices and liver. These genes were also hypermethylated in adult DS brain (specifically in neurons) and blood. This suggests that constitutive hypermethylation occurs early in development (during embryogenesis before separation of germ layers), affecting multiple cell types and tissues. In a mouse model, it has been shown that *de novo* methylation during early embryo development regulates the stochastic expression of different *Pcdh* isoforms at the individual cell level, thus generating single neuron diversity. The clustered protocadherins were all upregulated in *Dnmt3* knockout mice.[@cit0052] Consistent with their increased promoter methylation, expression of the *PCDHGA* and *B* genes was decreased in fetal DS cortex. *PCDHGC* genes, which are ubiquitously expressed and not regulated in the same way as subfamilies A and B,[@cit0052] were neither differentially methylated nor differentially expressed in DS brain. Remarkably, *CELSR3* was upregulated, suggesting that increased methylation in DS cortex abrogates a repressor activity or confers an enhancer-like activity.[@cit0053]

*PCDHG* genes encode transmembrane receptors with an intracellular, a transmembrane, and an extracellular domain. The proteins are present in most neurons and localized at synapses but also in axons and dendrites.[@cit0054] Different *PCDHG* knockout mouse models suggest a role for gamma protocadherins in promoting dendritic self-avoidance, arborization, and synaptic development in cortical neurons.[@cit0055] In contrast, the CELSR3 cell surface protein appears to suppress dendrite outgrowth.[@cit0059] The opposing effects of gamma protocadherins and CELSR3 on neurite growth regulation imply that transcriptional downregulation of *PCDHG* genes and upregulation of *CELSR3* act synergistically, both inhibiting dendrite arborization and growth in the developing DS cortex. Although neuronal density appears to be normal, DS fetal brains are characterized by reduced dendrite branching and impaired synaptosomal structure. Dendritic and axonal development is abnormal in fetal DS brains, including cortical lamination defects, reduced dendritic arborization, reduced number of synapses, and dendritic spine structural anomalies.[@cit0002]

Strong epigenetic effects were also observed in *CPT1B*, which showed increased gene body methylation and mRNA expression in DS fetal cortex. A published data set[@cit0028] revealed that this hypermethylation persists in the adult DS brain. Moreover, differential *CPT1B* methylation was reported in blood leukocytes, buccal epithelial cells, placenta, and brain of DS patients,[@cit0023] consistent with constitutive methylation changes. *CPT1B* on chromosome 22 is one of 3 carnitine palmitoyltransferase 1 genes that is mainly expressed in heart and skeletal muscle.[@cit0060] It encodes a mitochondrial enzyme, regulating entry of long chain fatty acids into the mitochondria. The *NOX5* gene on chromosome 15 exhibited gene body methylation and decreased expression in DS brain. *NOX5* is a calcium-dependent NADPH oxidase family protein that produces superoxide and functions as a calcium-dependent proton channel.[@cit0061] Dysregulation of *CPT1B* and *NOX5* may be involved in mitochondrial dysfunction and oxidative stress in DS brains. The link between reactive oxygen species (ROS) and DS neuropathology dates back to early observations that superoxide dismutase 1 (*SOD1*), a key enzyme in the free radical metabolism, is overexpressed from the DS critical region on chromosome 21.[@cit0062] Accumulating evidence from more than 2 decades suggests that increased ROS production and/or deficient antioxidant capacity contribute to brain damage (cell death) and cognitive impairment in DS and Alzheimer disease.[@cit0004] More recently, mitochondrial dysfunction has been found in the brains of patients with different psychiatric disorders.[@cit0065] *CPT1B* expression was altered in brain (amygdala) and blood of a rat stress model as well as in blood of patients with posttraumatic stress disorder.[@cit0066]

Because of legal and ethical restrictions (which differ between countries), there is only limited access to fetal brain samples and the quality of tissue samples is often not optimum. Our control samples were from spontaneous or induced abortions, mainly due to amniotic infection or placental problems. Although we cannot exclude that the various pathologies (of the control group) and postmortem times (\<24 h to 72 h) affect methylation patterns in individual samples, this does not explain the observed methylation differences between DS and control cortices. The majority of DS samples were from induced abortions, representing the whole spectrum of DS pathologies. One advantage of our study is that all fetuses underwent autopsy by an experienced pediatric pathologist and frontal cortex tissue was dissected from a well-defined area (BA10), compared to a more comprehensive data set[@cit0029] using undissected fetal brain tissue (cerebrum) as well as adult frontal and cerebellar cortex. Unfortunately, we could not reliably sort neuronal cells and non-neuronal cells from frozen fetal cortex samples. However, hypermethylation of the *PCDHG* cluster was validated in adult DS neurons and is consistent with the observed expression changes. In addition, some of our results were validated in fetal and adult DS brain,[@cit0028] using publicly available data. Although studies on a limited number of fetal brain samples are likely polluted with false negatives and false positives, it is reassuring that there is a significant overlap between DS-specific changes observed in different studies.

Outlook {#s0003-0001}
-------

This study presents a thorough analysis of methylation abnormalities in the developing DS brain. Our results suggest that accelerated DNA methylation aging, which has been reported in adult DS brain,[@cit0028] already starts *in utero*. Methylation-dependent downregulation of *PCDHG* subfamily A and B genes is expected to affect wiring processes in the developing cortex and, consequently, contribute to cognitive impairment in DS. Epigenetic dysregulation of *CPT1B* and other genes may perturb mitochondrial functions, leading to brain cell damage. Constitutive hypermethylation of *PCDHG* and *CPT1B* in brain and blood can be exploited as epigenetic biomarkers. It will be interesting to study the correlation between *PCDHG* blood methylation levels and highly variable DS phenotypes, in particular cognitive impairment.

Blood methylation changes of *PCDHG* genes were also reported in patients with Williams Beuren and 7q11.23 duplication syndrome.[@cit0067] The observed dysregulation of *PCDHG* genes in different chromosome disorders with cognitive deficits indicates novel avenues for clinical management and maybe even therapeutic interventions of patients with cognitive impairment. In contrast to the trisomy 21, epigenetic marks are in principle reversible. It has been shown that *PCDHG* genes[@cit0068] and *CELSR3*[@cit0059] can be pharmacologically modulated by protein kinase C and calcineurin inhibitors. Thus, similar to epigenetic drugs for cancer treatment, it may be feasible to develop epigenetic therapies for enhancing cognition and/or phenotypes in DS.[@cit0031]

Conditional knockout mice with *PCDHG*^*−/−*^ cortex showed reduction in the dendrite arborization complexity of pyramidal neurons.[@cit0056] Similar dendritic abnormalities in cortical neurons have been described in DS and DS mouse models.[@cit0005] Unfortunately, the cortical phenotype has not been examined in mice lacking only subsets (A1-A3 and C3-C5, respectively) of the *PCDHG* cluster.[@cit0057] It will be interesting to analyze whether and to which extent the different *PCDHG* knockout mouse models show cortical and other physical abnormalities of DS. If so, these mouse models may become valuable for the development of new drugs and maybe prenatal interventions preventing the negative effects of *PCDHG* dysregulation in DS.

Materials and methods {#s0004}
=====================

Samples {#s0004-0001}
-------

Tissue samples (Supplementary Table S1) were obtained from fetuses after spontaneous and induced abortions and underwent diagnostic examination at the Department of Pathology at Mainz University Medical Center. Use of excess tissue materials for scientific analyses was approved by the ethics committees of the Landesärztekammer Rheinland-Pfalz (no. 837.103.04_4261) and the Julius Maximilians Universität Würzburg (no. 262/14). Gestational age of each fetus was determined by foot length measurements (in mm) and last menstrual period. Following autopsy, the fetuses were photo documented, measured, weighed, and X-rayed in 2 levels. The postmortem time was determined using anamnestic data and autolytic processes. Chromosome (GTG banding) analyses were performed on primary fibroblast cultures from Achilles tendon. All DS samples included in this study displayed a complete extra copy of chromosome 21 (47,XX,+21 or 47,XY,+21). All controls showed normal karyotypes. The causes for abortion were vastly different, ranging from amniotic infections and placental abnormalities to various syndromes. Cortex tissues were dissected from the frontal lobe, Brodmann area BA10 (16 DS and 28 controls), the temporal lobe, BA38 (14 DS and 21 controls), and the occipital lobe, BA17/18 (15 DS and 21 controls). Liver tissue samples (14 DS and 38 controls) were obtained after an upper median incision to the abdomen. Adult cortices were obtained from 2 DS patients (from the Neurobiobank Munich and 12 suicide completers/sudden-death controls. Cortex tissue was dissected from the frontal pole, Brodman area BA10. Adult frontal cortex tissues of 2 DS and 10 controls were sorted into neuronal and non-neuronal cell using a NeuN-specific antibody, as described previously.[@cit0040]

For DNA and RNA preparation, tissue samples were disrupted using a Precellys24 high-throughput homogenizer (Peqlab, Erlangen, Germany). Genomic DNA was isolated with the DNeasy blood and tissue kit (Qiagen, Hilden, Germany). Bisulfite conversion was performed with 1 μg DNA each using the EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA). Amount and quality of DNA were determined with a Nanodrop spectrophotometer (NanoDrop, Wilmington, DEL, USA). The ratio of absorbance at 260 vs. 280 nm was around 1.8 for all samples, indicative of pure DNA. Total RNA was isolated with the RNeasy lipid and tissue mini kit (Qiagen). Amount and quality of DNA and RNA were analyzed with an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA) system using the RNA 6000 Nano kit (Agilent).

Methylation array analysis {#s0004-0002}
--------------------------

After bisulfite conversion, 72 samples (16 DS and 27 control fetal frontal, 8 DS and 8 control fetal temporal, 2 DS and 9 control adult frontal cortices) including some duplicates were whole-genome amplified, enzymatically fragmented, and analyzed with 6 HumanMethylation450 BeadChips (Illumina, San Diego, CA, USA), according to the manufacturer\'s protocol. To avoid batch effects, the 12 arrays on each chip were hybridized with matched DS and control samples as well as samples from different brain regions and all chips were processed together. The arrays were scanned with an Illumina iScan.

Resulting array data (NCBI GEO accession number GSE73747) were preprocessed using the RnBeads pipeline[@cit0069] with default settings. Sites overlapping SNPs, sites not in the CpG context and probes flagged as unreliable based on the corresponding detection *P* value were removed. Furthermore, 11,169 probes on the sex chromosomes were excluded, leaving a total number of 465,572 probes for subsequent analyses (of \> 485,000 CpGs covering 99% of RefSeq genes with promoter, first exon, gene body, 5′ and 3′ UTRs, and 96% of CpG islands). The signal intensity values were normalized using the SWAN normalization method,[@cit0037] as implemented in the minfi package.[@cit0070] Different normalization methods were used to confirm the unique methylation profile of chromosome 21. In addition to SWAN,[@cit0037] we applied dasen normalization[@cit0034] with and without subsequent Type II probe bias correction with the BMIQ method[@cit0035] as well as a novel functional normalization approach (Funnorm) for situations where substantial global differences in methylation can be expected.[@cit0036]

Differential methylation analysis has been performed using the moderated T-test model as implemented in the limma package[@cit0071] based on β values of the fetal samples. A site-wise analysis was conducted based on a model with brain region, chromosomal status, and gestational age as covariates, including the first order interaction between the covariates. Reported *P* values are based on the moderated T statistics of the main effects or interaction terms. A set of pan-tissue hypermethylated sites has been created based on our fetal cortex data set and methylation profiles from human blood samples.[@cit0026] Analogously to the approach described,[@cit0029] we selected all sites hypermethylated in both tissues with a β difference \> 0.15 and *P* \< 0.005. The set of CTCF sites for the motif analysis was obtained from the authors of a conceptually related study.[@cit0029]

For subsequent gene-based analyses the GENCODE catalog (Version 19, GRCh37 genome build) was used. The catalog comprises a total of 57,820 genes from which only the subset of 19,430 protein coding genes was included in the analyses. Promoters were defined as regions flanking the transcription start sites (2,000 bp upstream and 200 bp downstream). To determine the significance of methylation changes over the promoter regions, the *P* values from the site-wise analysis were aggregated using the RnBeads function "combineTestPvalsMeth," which is based on the weighted inverse χ^2^ method for correlated significance tests.[@cit0072] The site-wise methylation differences have been averaged over the promoter regions, and the promoters have been ranked using a combined rank approach. This combines the effect size (β difference) and statistical significance (*P* values) ranking the regions according the maximum rank of *P* value and negative absolute difference of β values. The Gene ontology enrichment analysis and visualization (GOrilla) tool was used to identify enriched GO terms in ranked lists of genes.[@cit0039]

Bisulfite pyrosequencing {#s0004-0003}
------------------------

PCR and sequencing primers (Supplementary Table S9) were designed using the PyroMark Assay Design 2.0 software (Qiagen). PCR reactions were performed in a total volume of 25 µl using the FastStart Taq DNA Polymerase system (Roche Diagnostics, Mannheim, Germany). The 25-μl reaction consisted of 2.5 μl 10x PCR buffer, 20 mM MgCl~2~, 0.5 μl dNTP (10 mM) mix, 10 pmol of forward and reverse primer, 1 IU of FastStart Polymerase (Roche Diagnostics), 1 μl (approximately 100 ng) bisulfite converted template DNA, and 18.8 μl PCR-grade water. To reduce technical noise (batch effects), bisulfite conversion and PCR (of matched DS and control samples) were performed in 96-well microtiter plates. Pyrosequencing was performed on a PyroMark Q96 MD system with PyroMark Gold Q96 CDT reagents (Qiagen). Methylation values were quantified using the Pyro Q-CpG software. The average methylation difference between technical replicates was approximately one percentage point. To obtain a common value for each gene the β values of CpG sites have been averaged over the gene for each tissue separately. To account for a potential effect of gestational age a linear model was subsequently fitted to each gene and tissue separately including chromosomal status and gestational age as covariates. All *P* values have been corrected for multiple testing using the method of Bonferroni-Holm.[@cit0073]

Targeted RNA sequencing {#s0004-0004}
-----------------------

A customized TruSeq RNA expression panel with 135 assays targeting 38 genes, in particular the *PCDHG* gene cluster on chromosome 5, *CELSR3, CPT1B, NOTCH4, NOX5*, 3 genes (*BACE, CBS*, and *PRDM15*) on chromosome 21, and 5 internal control genes, was designed by Illumina DesignStudio. A smaller panel with 25 assays targeted 4 differentially methylated genes (*DND1, EFCAB4A, TNFRSF6B*, and *UNC45A*), 6 epigenetic modifiers (*CHAF1B, CBS, DNMT3L, DYRK1A, MIR155*, and *MIR802*) and 2 other genes (*APP, SOD1*) on chromosome 21, *DNMT3A, DNMT3B, NRSF*/*REST*, and 4 internal control genes. cDNA was synthesized from 15 DS and 20 control fetal frontal cortex samples using ProtoScript II Reverse Transcriptase. Subsequent steps were performed according to the TruSeq targeted RNA expression guide. All RNA samples were analyzed in technical duplicates. FirstChoice Human Brain Reference RNA (ThermoFisher Scientific, Waltham, MA, USA) was used as positive control, as recommended in the Illumina protocol. Extension-ligation products of all samples were amplified with a 96 indexing combination of adapters (A501-A508 and R701-R712) in the TruSeq targeted RNA index kit A. PCR products were purified with AMPure XP beads (Beckman Coulter, Fullerton, CA, USA), pooled, and quantified with a 2100 Bioanalyzer and the Agilent DNA 1000 Kit. The TruSeq RNA library was sequenced (single reads) for 50 cycles and dual-index 6 and 8 cycles using Illumina MiSeq and the MiSeq Reagent Kit v3.

Mapping and counting were performed with Illumina GenomeStudio software according to the manufacturer\'s protocol. Assays comprising \< 100 reads in total and samples with \< 1,000 reads in total were excluded. Differential expression analysis was performed using the limma modeling framework[@cit0071] in combination with the "voom" method,[@cit0074] which has been specifically designed for the analysis of count data in RNASeq experiments. The correlation of technical replicates was estimated with the "duplicateCorrelation" function and modeled by a mixed linear model implemented in the limma package. Chromosomal status and gestational age were incorporated as covariates in the model to obtain estimates of DS corrected for gestational age. All *P* values have been corrected for multiple testing using the Benjamini-Hochberg method.[@cit0075]

Bioinformatics analyses of published data sets {#s0004-0005}
----------------------------------------------

Genomic coordinates of DMRs in *DNMT3A, DNMT3B*, and *DNMT3A/DNMT3B* knockout cell lines (Supplementary Table S7) have been obtained from a recently published data set.[@cit0042] Probes on HumanMethylation450 BeadChip were mapped to these regions. Counting only CpGs falling within these regions resulted in 7,508 probes for the enrichment analysis. To test for the enrichment of DNMT binding regions among the differentially methylated sites the "camera" algorithm of the limma package has been applied.[@cit0076] This method has originally been designed as a competitive gene set enrichment method. However, it can also be used to test whether a set of CpG sites is highly ranked relative to other sites in terms of differential methylation. Here, the CpG sites of the DNMT knockout DMRs were used as the input set for the "camera" analysis. As adjacent sites usually show a correlation due to spatial proximity, this technique is particularly adequate as it accounts for potential inter-site correlation.

A list of potential REST binding sites was generated from the UCSC ENCODE transcription factor ChIPseq Uniform Peaks (<http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeAwgTfbsUniform/>). These data sets were generated by the ENCODE TFBS ChIP-Seq production groups and comprise 91 different human cell types under diverse conditions. These include REST antibody enrichment for 10 cell types, of which the human embryonic stem cell (H1-hESC) data was used for analysis. CpGs on the HumanMethylation450 BeadChip were mapped to REST binding regions and only CpGs within the ChIPSeq peak boundaries were considered as defining an overlap. Differential methylation for each binding region was tested by the self-contained enrichment method as implemented in the "fry" function, which can be regarded as a faster version of the "mroast" method in the limma package.[@cit0077]

Methylation profiles of adult blood were downloaded from the NCBI GEO database (accession no. GSE52588). The data set comprises 450K methylation array profiles of whole blood samples from 29 Down syndrome patients (DSP), using their unaffected mothers (DSM) and siblings (DSS) as controls.[@cit0026] The data has been processed using the minfi pipepline.[@cit0070] After removal of SNP-containing probes, the 467,971 remaining β values were normalized using the dasen method as implemented in the wateRmelon package.[@cit0034] Differential methylation analysis was performed using the linear modeling approach of limma as described above.[@cit0071] To account for the relationship structure the family identifier of the trios has been included as a factor covariate in the model. Methylation profiles of adult brains were downloaded from the NCBI GEO database (accession number GSE63347). The data set included 71 samples from multiple brain regions (cerebellum, temporal, occipital and frontal cortex).[@cit0028] Preprocessing and differential methylation analysis were performed as described above focusing on the contrast between male DS and normal male control cortices.

DNA methylation age was calculated, as described previously.[@cit0038] A measure of age acceleration was defined as the residual of a linear model regressing DNA methylation age on chronological age in controls.[@cit0028] Samples with a DNA methylation age higher than expected have positive residuals, indicating accelerated aging. The significance of the age acceleration effect has been assessed using a Wilcox rank sum test.
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